Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1430

Benzinga Newsdesk www.benzinga.com Positive 83.8%

Neg 0% Neu 0% Pos 83.8%

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:LLY) with a Overweight and raises the price target from $1419 to $1430.